Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Earnings

see more
Q3 2021Est.ActualSurprise
EPS
(EXPECTED)2021-11-04
REV
Q2 2021Est.ActualSurprise
EPS-0.2300.230 0.4600
REV31.810M72.649M40.839M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
TBIO